Betting On A Winning Horse: CBD Search Engine Inquires Continue to Grow

 In NASDAQ:CRON, NASDAQ:NEPT, NASDAQ:TLRY, NYSE: ACB, NYSE:STZ, OTC: DIRV, OTC: MMNFF, OTCQB:CWBHF, OTCQB:MMNFF, OTCQB:MSPC, QTCQB:LDSR

New York, NY May 10, 2019 – Stock Market Press is a leading financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network brings Cannabidiol to the table.

Over the past year, search engine inquires for Cannabidiol (‘CBD’) has continued to climb. Long before the 2018 Farm Bill was even a thought, the general population has been learning and researching CBD and the benefits of its use. CBD has a long history, going back thousands of years, but until recently has seen widespread use halted by the negative stigma of marijuana and its psychoactive effects (caused by THC) along with ‘fake’ CBD products. CBD has 0.3% of THC or less, causing no psychoactive effects but still providing the benefits of cannabis.

The incredible increase in demand has seen companies like GW Pharmaceuticals plc (NASDAQ:GWPH), Marathon Group Corp. (OTC:PDPR) and Curaleaf Holdings, Inc. (CSE:CURA) (OTC:CURLF) jump on this fantastic opportunity. This isn’t a ‘flash in the pan’ market but the beginning of a long term ‘permanent’ industry.

GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex

– Achieved primary efficacy measure with both EPIDIOLEX doses as compared to placebo –

– Represents the fifth consecutive positive Phase 3 pivotal trial for EPIDIOLEX –

– Expect to file sNDA in Q4 2019 –

GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ:GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today (May 6th, 2019) announced positive top-line results of a randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX® (cannabidiol or CBD) CV in the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare and severe form of childhood-onset epilepsy. In this trial, EPIDIOLEX met its primary endpoint, which was the reduction in seizure frequency compared to baseline of the Epidiolex 25 mg/kg/day dose group vs placebo (p=0.0009).  Results for both the 25 and 50 mg/kg/day dose groups were similar, with seizure reductions of 48.6% and 47.5% from baseline respectively, vs 26.5% for placebo (50 mg/kg/day vs placebo, p=0.0018). All key secondary endpoints were supportive of the effects on the primary endpoint. The safety profile observed is consistent with findings from previous studies, with no new safety risks identified.

Marathon Group’s Wholly Owned Subsidiary, MarathonRx, Has Signed a Manufacturing and Supply Agreement for a 1,500mg Nano-Pure Ultra CBD Drops Product, the First of Many Products

Marathon Group Corp. (OTC: PDPR) (the “Company” or “Marathon”) is pleased to announce our subsidiary, MarathonRx, has secured their first product, 1,500mg Nano-Pure Ultra CBD Drops via a signed agreement with a well-respected NY based cannabinoid specialty company.

Nano-Pure Ultra CBD Drops are a fast absorbing sublingual method of CBD delivery. These drops are made with pure hemp extract, along with other natural ingredients, to increase absorption for fast acting relief. Our cannabinoid delivery system increases the CBD delivery by over 450%, compared to hemp on its own, due to our extremely small CBD particle size.

The market for Hemp CBD oil is set to explode over the next few years. As discussed in our recent press release, the size of the hemp CBD consumer market alone is projected to reach $22 billion dollars per year in sales by 2022 (Brightfield Group).

As a result of recent consumer and industrial pressure, the US has passed the Farm Bill, easing federal restrictions on hemp production. This will allow an increase in production and a subsequent decrease in costs, increasing the market potential to a larger portion of the population. A TechNavio report (https://www.technavio.com/report/global-cbd-oil-market-analysis-share-2018) indicates the CBD oil market is expected to grow by 31% year over year through 2022.

Ongoing scientific research into the uses of CBD oil for pain, anxiety/depression, cancer related symptoms, acne, neuroprotective properties, heart health, diabetes, anti-inflammatory properties and many more. A search on https://www.ncbi.nlm.nih.gov/pubmed/?term=cbd+oil for the term ‘CBD oil’ brings up a number of studies regarding the widespread benefits of CBD oil use.

Curaleaf Acquires Rights to Cultivation and Processing Capacity in Ohio

Curaleaf Holdings, Inc. (CSE:CURA) (OTC:CURLF) (“Curaleaf”), a leading vertically integrated cannabis operator in the United States , today announced it has signed a definitive agreement granting it an option to acquire Ohio Grown Therapies (“OGT”) medical cannabis cultivation and processing licenses and facility in Ohio. OGT was awarded preliminary cultivation and processing licenses by the Ohio Department of Commerce in 2018.

OGT is building out its 32,000 square foot cultivation and processing facility in Johnstown, Ohio . At completion, the facility will be comprised of 15,000 square feet for two-tier cultivation and 7,500 square feet for processing. Curaleaf is advising OGT on the buildout and expects to acquire OGT’s cultivation and processing licenses as well as the lease to the Johnstown facility in the second half of 2019, subject to regulatory approval.

The CBD market is still in its infancy, but learning to walk very quickly due to the explosive demand for CBD products. This demand is worldwide. FDA approval for a CBD based product has sent shock-waves, not just domestically, but around the world. This gives CBD a real world presence, not longer the ‘snake oil’ salesman stigma that has haunted it in the past.

Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.

Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.

Contact:

Stock Market Press
110 Wall St.
New York, NY 10005
info@wordpress-61181-1001021.cloudwaysapps.com
https://twitter.com/PressStock

Safe Harbor Statement:

Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

See Stock Market Press disclaimer: http://www.stockmarketpress.com/disclaimer/

SOURCE: Stock Market Press

 Stock News Report Interview

Stock News Report Interview